Citation

Phase 3 Clinical Trial of Investigational Vaccine for COVID-19 Begins

Moderna, Inc.

NIH News Release (2020)

TL;DR

Vaccine designed within 2 days of sequence publication

Documents the timeline of mRNA-1273 development: genetic sequence published January 11, 2020; vaccine designed within 2 days; first batch shipped February 24; Phase 1 trials began March 16, 2020; FDA Emergency Use Authorization December 18, 2020.

Illustrates how timing and random sampling during crisis bottlenecks can determine which organizations emerge with breakthrough capabilities fixed.

Key Findings from Moderna (2020)

  • Vaccine designed within 2 days of sequence publication
  • Phase 1 trials began 65 days after sequence published
  • FDA EUA granted 11 months after pandemic began

Related Mechanisms for Phase 3 Clinical Trial of Investigational Vaccine for COVID-19 Begins

Related Companies for Phase 3 Clinical Trial of Investigational Vaccine for COVID-19 Begins

Tags